More on VNDA
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $5.17 |
|
|||
| Open | $5.17 | ||||
| 52 Wk High | $18.00 | ||||
| 52 Wk Low | $6.91 | ||||
| Day High | $5.18 | ||||
| Day Low | $5.00 | ||||
| P/E | N/A | ||||
| EPS | $-0.67 | ||||
| Volume | 2,577,906 | ||||
- Vanda reports positive Phase III results for HETLIOZ in sleep disorder
- Vanda Pharmaceuticals Announces Positive Phase III Results for HETLIOZ®(tasimelteon) in Delayed Sleep-Wake Phase Disorder
- Oppenheimer Starts Vanda Pharmaceuticals (VNDA) at Outperform
- EU grants Vanda's imsidolimab first orphan status for rare skin disease
- Vanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European Commission
- NEREUS™ Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C.
- Form SCHEDULE 13G Vanda Pharmaceuticals Filed by: MILLENNIUM MANAGEMENT LLC
- This biotech stock offers a buying opportunity: B. Riley
- Form SCHEDULE 13G Vanda Pharmaceuticals Filed by: AQR CAPITAL MANAGEMENT LLC
- Vanda Pharmaceuticals (VNDA) PT Lowered to $12 at B.Riley
Entities mentioned with VNDA
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Twitter | View Related Stories »
- 13G | View Related Stories »
- Definitive Agreement | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Show More...
